Drug intelligence / Profile preview

Xingnao Kukeiya Tablets

Development stage: Unknown
Lead developer: Xinjiang Yinduolan Pharmaceutical
Administration: Oral

Overview

Xingnao Kukeiya Tablets is a traditional Uyghur medicine developed by Xinjiang Huakang Pharmaceutical Co., Ltd. for the treatment of migraine. It is specifically indicated for adults with migraine with or without aura, particularly those classified under the abnormal phlegmatic type in traditional Uyghur medicine theory. The drug is currently in Phase III clinical development in China (Trial ID: CTR20210690), where it is being evaluated in a randomized, double-blind, placebo-controlled study to assess its efficacy and safety.

Brand names: Xingnao Kukeiya Tablets
Other names: Xingnao Kukeiya Tablets

Beyond the preview

Go deeper on Xingnao Kukeiya Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xingnao Kukeiya Tablets.

Explore the full profile